undamentalytics Newsletter
Sign in

Abcellera Biologics Inc. (ABCL) stock

Add to watchlist

Add holding +

NASDAQ: ABCL Nasdaq Biotechnology Next results ~November 9, 2026

C Fundamentals grade

Abcellera Biologics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Abcellera Biologics Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Abcellera Biologics Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 0 selling9 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds73 adding, 80 cuttingOf 31 active managers that changed their stake, 14 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Abcellera Biologics files

Where Abcellera Biologics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $66m, up 101.3% on a year earlier, slower than the 242.7% growth a quarter earlier. Free-cash-flow margin rose to -180.8% from -422.8% a year earlier. Operating margin widened to -340.3% from -847.6%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks.

Our model value for Abcellera Biologics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Abcellera Biologics Inc.'s trailing-twelve-month revenue grew 101.3% year on year, with a free-cash-flow margin of -180.8%. Where it lags: change in growth rate of -141.4pp ranks 160 of 172 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 101.3% (-141.4pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 101.3% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 507.4 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 141.4 points lower than a quarter earlier.
  • Loss-making. Operating margin is -340.3%: costs exceed revenue.
  • Burning cash. Free cash flow was -180.8% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 77.2% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • High sales multiple. The shares trade at 51 times revenue while operating margins remain thin.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.18 against an average estimate of -$0.17: missed by 9.1%
Revenue
$4m, down 76.3% on a year earlier
Share reaction
+7.2% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 9, 2026; average EPS estimate -$0.18

Abcellera Biologics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-9.4%
  • 1 week-7.9%
  • 1 month-19.1%
  • This year+225.1%
  • 1 year+100.4%
  • 5 years-36.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$66.2M
Operating margin
-340.3%
Net margin
-248.8%
EPS (TTM, diluted)
$-0.55

Growth

Revenue growth
+101.3%
Change in growth rate
−141.4 pts
Share count change
+1.7%

Cash

Free cash flow (TTM)
-$120M
FCF margin
-180.8%
Stock pay % of revenue
77.2%

Earnings

Last results
August 5, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Announcement
  3. Announcement
  4. Results
  5. Announcement
  6. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Abcellera Biologics Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Abcellera Biologics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.41 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.6 ~$1.5–$1.6 Left out: out of range vs price (0.14x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.3 ~$0.3–$1.1 Left out: out of range vs price (0.03x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Abcellera Biologics Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$40.24$14.30$10.13$5.71$2.93$3.42$11.12
Market value$10.6bn$4.6bn$3.2bn$1.7bn$862m$1.0bn$3.4bn
+ Net debt (− = net cash)−$594m−$476m−$387m−$133m−$156m−$129m−$120m
Enterprise value$10.0bn$4.1bn$2.8bn$1.5bn$706m$893m$3.2bn
Multiples
Price / sales 45.4x12.1x6.6x43.4x29.9x13.6x50.7x
Price / earnings 89.0x29.7x20.1x————
Price / free cash flow n/m24.5x15.4x————
EV / EBITDA 62.1x18.6x11.5x————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

17 /100

Weak moat

How hard Abcellera Biologics's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -7.8% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -210.2%; its worst year was -847.6%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 2 of 6 years, at a median -154.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (22 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $6m and EPS of −$0.18 (range −$0.20 to −$0.16) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.67 −38% $26m −65%
Next −$0.76 −13% $28m +7%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +7.6% on 90 days ago. In the last 30 days, 1 analyst raised Abcellera Biologics Inc.'s forecast and 3 cut it.

Consensus EPS forecast Abcellera Biologics Inc., last 90 days
−$0.80 −$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.63 Current fiscal year, 60 days ago: −$0.66 Current fiscal year, 30 days ago: −$0.67 Current fiscal year, 7 days ago: −$0.67 Current fiscal year, Now: −$0.67 −$0.67 Next fiscal year, 90 days ago: −$0.70 Next fiscal year, 60 days ago: −$0.71 Next fiscal year, 30 days ago: −$0.76 Next fiscal year, 7 days ago: −$0.76 Next fiscal year, Now: −$0.76 −$0.76

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.63−$0.70
60 days ago −$0.66−$0.71
30 days ago −$0.67−$0.76
7 days ago −$0.67−$0.76
Now −$0.67−$0.76

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.17 −$0.18 −9.1%
Mar 2026 −$0.20 −$0.14 +29.1%
Dec 2025 −$0.18 −$0.03 +83.3%
Sept 2025 −$0.16 −$0.19 −17.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

12 analysts, Oct 2026
Buy1192%
Hold18%
Sell00%

Monthly trend

  1. Oct 202629112
  2. Sep 202628111
  3. Aug 2026189
  4. Jul 2026189

Counts of recommendations published by analysts covering Abcellera Biologics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
12.2%
of tradable shares
Days to cover
5.65
at average volume
Short interest, 1 month
−9%
to October 15, 2026
Held by institutions
41%
of shares
Held by insiders
21.7%
of shares
Employees
562
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +100.4%

$5.55 on October 31, 2025 to $11.12

ThenNowEffect
Revenue (last 12 months) $33m $66m +101.3%
P/S multiple 50.1x 50.7x +1.3%
Share count 297m 302m −1.7%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +136.6%

$4.70 on November 3, 2023 to $11.12

ThenNowEffect
Revenue (last 12 months) $145m $66m −54.4%
P/S multiple 10.0x 50.7x +405.4%
Share count 310m 302m +2.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ABCL−65%−29%−44%−49%+17%+225%
Industry peers (median)−35%−57%−17%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ABCL33%42%42%42%50%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ABCL−76%−60%−65%−60%−46%−40%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since December 11, 2020: 97% from December 11, 2020 to April 8, 2025. Getting back needed a 2952% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.78 – $14.82
From 52-week high
−25.0%
vs 50-day average
−9.5%
vs 200-day average
+61.5%
Volatility (1 year)
86%
Beta vs S&P 500
2.61

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±7.2%
After a week
5 up, 7 down
typical move ±16.3%
After a month
6 up, 6 down
typical move ±18.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +7.2% −0.4% +70.0% +90.0%
May 11, 2026 −5.5% +0.1% −20.6% −2.9%
February 24, 2026 +5.3% +1.6% +22.4% +11.9%
November 6, 2025 −16.6% −1.0% −22.8% −23.5%
August 7, 2025 +3.2% +0.7% +9.2% +1.2%
May 8, 2025 +1.0% +0.6% +0.5% +24.9%
February 27, 2025 −11.5% −0.1% −18.5% −20.9%
November 4, 2024 −0.4% +1.0% +15.4% +6.2%
August 6, 2024 −4.7% +0.2% −3.3% −12.0%
May 7, 2024 −6.6% +0.1% −7.1% −8.0%
February 20, 2024 −9.9% −0.5% −4.1% −11.4%
November 2, 2023 +14.1% +2.8% −1.9% +12.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Abcellera Biologics Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Abcellera Biologics Inc.
$0 $20M $40M $60M $80M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $50.4M Revenue (TTM), FY23 Q4: $38M Revenue (TTM), FY24 Q1: $35.8M Revenue (TTM), FY24 Q2: $33.1M Revenue (TTM), FY24 Q3: $33M Revenue (TTM), FY24 Q4: $28.8M Revenue (TTM), FY25 Q1: $23.1M Revenue (TTM), FY25 Q2: $32.9M Revenue (TTM), FY25 Q3: $35.3M Revenue (TTM), FY25 Q4: $75.1M Revenue (TTM), FY26 Q1: $79.2M Revenue (TTM), FY26 Q2: $66.2M $66.2M

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $50.4M
FY23 Q4 $38M
FY24 Q1 $35.8M
FY24 Q2 $33.1M
FY24 Q3 $33M
FY24 Q4 $28.8M
FY25 Q1 $23.1M
FY25 Q2 $32.9M
FY25 Q3 $35.3M
FY25 Q4 $75.1M
FY26 Q1 $79.2M
FY26 Q2 $66.2M
Revenue growth, TTM YoY Abcellera Biologics Inc.
-100% 0% 100% 200% 300% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -91.6% Revenue growth, TTM YoY, FY23 Q4: -92.2% Revenue growth, TTM YoY, FY24 Q1: -80.2% Revenue growth, TTM YoY, FY24 Q2: -77.2% Revenue growth, TTM YoY, FY24 Q3: -34.6% Revenue growth, TTM YoY, FY24 Q4: -24.2% Revenue growth, TTM YoY, FY25 Q1: -35.4% Revenue growth, TTM YoY, FY25 Q2: -0.5% Revenue growth, TTM YoY, FY25 Q3: 7.2% Revenue growth, TTM YoY, FY25 Q4: 160.6% Revenue growth, TTM YoY, FY26 Q1: 242.7% Revenue growth, TTM YoY, FY26 Q2: 101.3% 101.3%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -91.6%
FY23 Q4 -92.2%
FY24 Q1 -80.2%
FY24 Q2 -77.2%
FY24 Q3 -34.6%
FY24 Q4 -24.2%
FY25 Q1 -35.4%
FY25 Q2 -0.5%
FY25 Q3 7.2%
FY25 Q4 160.6%
FY26 Q1 242.7%
FY26 Q2 101.3%
Operating margin (TTM) Abcellera Biologics Inc.
-1500% -1000% -500% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -414.6% Operating margin (TTM), FY23 Q4: -623.8% Operating margin (TTM), FY24 Q1: -634.9% Operating margin (TTM), FY24 Q2: -814.7% Operating margin (TTM), FY24 Q3: -934.6% Operating margin (TTM), FY24 Q4: -1091.6% Operating margin (TTM), FY25 Q1: -1395.3% Operating margin (TTM), FY25 Q2: -847.6% Operating margin (TTM), FY25 Q3: -739.7% Operating margin (TTM), FY25 Q4: -289.0% Operating margin (TTM), FY26 Q1: -267.6% Operating margin (TTM), FY26 Q2: -340.3% -340.3%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -414.6%
FY23 Q4 -623.8%
FY24 Q1 -634.9%
FY24 Q2 -814.7%
FY24 Q3 -934.6%
FY24 Q4 -1091.6%
FY25 Q1 -1395.3%
FY25 Q2 -847.6%
FY25 Q3 -739.7%
FY25 Q4 -289.0%
FY26 Q1 -267.6%
FY26 Q2 -340.3%
FCF margin (TTM) Abcellera Biologics Inc.
-800% -600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -135.3% FCF margin (TTM), FY23 Q4: -317.7% FCF margin (TTM), FY24 Q1: -356.6% FCF margin (TTM), FY24 Q2: -515.5% FCF margin (TTM), FY24 Q3: -598.7% FCF margin (TTM), FY24 Q4: -648.4% FCF margin (TTM), FY25 Q1: -619.9% FCF margin (TTM), FY25 Q2: -422.8% FCF margin (TTM), FY25 Q3: -433.4% FCF margin (TTM), FY25 Q4: -231.7% FCF margin (TTM), FY26 Q1: -238.9% FCF margin (TTM), FY26 Q2: -180.8% -180.8%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -135.3%
FY23 Q4 -317.7%
FY24 Q1 -356.6%
FY24 Q2 -515.5%
FY24 Q3 -598.7%
FY24 Q4 -648.4%
FY25 Q1 -619.9%
FY25 Q2 -422.8%
FY25 Q3 -433.4%
FY25 Q4 -231.7%
FY26 Q1 -238.9%
FY26 Q2 -180.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 12 233 375 485 38 29 75 66
EBITDA −3 161 219 244 −213 −302 −199 −204
Operating income −4 156 204 217 −237 −315 −217 −225
Net income −2 119 153 159 −146 −163 −146 −165
Diluted EPS −$0.01 $0.45 $0.48 $0.50 −$0.51 −$0.55 −$0.49 −$0.55
Growth (year on year)
Revenue — +>999% +60.9% +29.4% −92.2% −24.2% +160.6% +101.3%
EBITDA — — +36.1% +11.6% −187.1% — — —
Operating income — — +31.0% +5.9% −209.6% — — —
Net income — — +29.1% +3.3% −192.4% — — —
Diluted EPS — — +6.7% +4.2% −202.0% — — —
Margins
EBITDA margin −21.6% 69.0% 58.3% 50.3% −559.7% <−999% −264.4% −307.8%
Operating margin −35.5% 66.9% 54.5% 44.6% −623.8% <−999% −289.0% −340.3%
Net margin −19.0% 51.0% 40.9% 32.7% −385.0% −564.8% −194.9% −248.8%
Free-cash-flow margin −11.2% 5.6% 49.6% 42.6% −317.7% −648.4% −231.7% −180.8%
Cash flow
Cash from operations 3 23 245 277 −44 −109 −131 −95
Capital spending 4 10 58 71 77 78 43 25
Free cash flow −1 13 186 207 −121 −187 −174 −120
Stock-based pay 1 8 31 49 64 68 56 51
Free cash flow after stock pay −2 5 155 157 −185 −255 −230 −171
Balance sheet
Cash — 594 476 387 133 156 129 120
Total debt — 0 0 0 0 0 0 0
Net debt (negative = net cash) — −594 −476 −387 −133 −156 −129 −120
Diluted shares 151m 263m 318m 315m 289m 294m 299m 302m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $1.3bn
Short-term assets $679mLonger-term assets $628m
What it owes, and who funded it · $1.3bn
Short-term liabilities $53mLonger-term liabilities $358mShareholders' equity $896m
  • Short-term assets cover short-term liabilities $679m of assets due within a year against $53m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $679m short-term assets against $358m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Abcellera Biologics Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.7%
year over year
R&D spending
298.9%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ABCL CYTK CUVL RXRX WVE VRDN Median
Revenue, last 12 months $66m $68m $64m $68m $71m $71m $56m
Revenue growth, last 12 months 101.3% −21.1% 5.2% 56.2% 202.3% >999% 12.6%
Revenue growth, 3-year average −23.0% 89.5% — 12.9% 20.7% 264.4% 13.7%
Revenue growth, latest quarter −76.3% −57.1% — 258.5% 72.9% 278.7% 10.2%
Gross margin — — 82.9% 29.2% — 54.5% 82.9%
Operating margin −340.3% <−999% 43.4% −725.4% −320.9% −569.7% −189.4%
Operating margin, 3-year average −667.5% <−999% — −995.4% −256.4% <−999% −363.5%
Net margin −248.8% <−999% 36.0% −697.1% −296.9% −544.1% −169.8%
Cash from operations / revenue −143.5% −820.8% 20.1% −455.1% −291.9% −468.7% −168.0%
Free-cash-flow margin −180.8% −858.2% 18.4% −458.0% −293.8% −471.0% −162.4%
Free-cash-flow margin, 3-year average −373.0% <−999% — −664.1% −148.0% <−999% −310.0%
Stock pay / revenue 77.2% 188.1% 2.5% 129.4% 52.8% 75.4% 20.0%
Change in share count 1.7% 4.9% 0.7% 32.7% 20.2% 42.0% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 101.3% 12.6% 39 of 172
Change in growth rate Growth -141.4pp -0.1pp 160 of 172
Operating margin Profitability -340.3% -189.4% 111 of 175
Net margin Profitability -248.8% -157.3% 105 of 180
Free-cash-flow margin Cash generation -180.8% -145.4% 94 of 176
Stock pay as % of revenue Cash generation 77.2% 19.2% 131 of 179
Change in share count Balance sheet 1.7% 7.9% 42 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $46.9M 62.5% ▲ 4372.8%
Research Fees $27.2M 36.2% ▲ 3.5%
Milestone Payments $1M 1.3% ▼ 33.3%
Geography
Region Revenue Share YoY
Canada $64M 85.2% ▲ 144.3%
United States $11.1M 14.8% ▲ 311.1%

From Abcellera Biologics Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$909M
Institutions reporting
150
Shares held vs prior quarter
▼ 6.6%
Positions opened / closed
37 / 26

Top buyers and sellers, Q2 2026: 73 institutions bought and 80 sold ; the biggest buyer was Bank Of America Corp (+3.1M shares) and the biggest seller Goldman Sachs Group Inc (−3.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Baker Bros. Advisors LP $259M 33.0M 28.5% ▲ 9.0%
Capital World Investors $107M 13.6M 11.7% ▲ 1.7%
Two Sigma Investments, LP $81.9M 10.4M 9.0% ▼ 1.2%
TD Waterhouse Canada Inc. $72.6M 9.6M 8.0% 0.0%
Bank Of America Corp $48.2M 6.1M 5.3% ▲ 104.7%
UBS Am, A Distinct Business Unit Of UBS Asset Management Americas LLC $33.9M 4.3M 3.7% ▼ 43.0%
Arrowmark Colorado Holdings LLC $32.2M 4.1M 3.5% 0.0%
Blackrock, Inc. $29.9M 3.8M 3.3% ▼ 5.8%
Driehaus Capital Management LLC $22.5M 2.9M 2.5% ▼ 28.8%
Tudor Investment Corp Et Al $16.2M 2.1M 1.8% ▼ 9.3%
Marshall Wace, LLP $14.9M 1.9M 1.6% ▲ 428.9%
UBS Group AG $14.7M 1.9M 1.6% ▼ 55.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Abcellera Biologics Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $2.7M 9 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $2.7M net buying
Insider Date Trade Shares Price Value
Hayden Michael R Director August 24, 2026 Buy 53,613 $10.64 $570,442
Montalbano John S. Director August 18, 2026 Buy 10,000 $11.03 $110,300
Booth Andrew Chief Financial Officer August 14, 2026 Buy 37,200 $10.32 $383,904
Hayden Michael R Director August 12, 2026 Buy 46,387 $10.37 $481,033
Montalbano John S. Director May 14, 2026 Buy 20,000 $4.77 $95,400
Booth Andrew Chief Financial Officer February 27, 2026 Buy 42,600 $3.42 $145,692
Thermopylae Holdings Ltd. 10% owner February 27, 2026 Buy 38,000 $3.44 $130,720
Thermopylae Holdings Ltd. 10% owner February 26, 2026 Buy 177,457 $3.27 $580,284
Montalbano John S. Director November 26, 2025 Buy 50,000 $3.57 $178,500

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 11, 2026
  • February 24, 2026
  • November 6, 2025
  • August 7, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Abcellera Biologics Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Abcellera Biologics Inc. in brief

What does Abcellera Biologics Inc. do?
Abcellera Biologics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Abcellera Biologics Inc.'s stock ticker?
Abcellera Biologics Inc. trades under the ticker ABCL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Abcellera Biologics Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Abcellera Biologics Inc. reported revenue of $66.2M, 101.3% higher than a year earlier, according to its SEC filings.
What is Abcellera Biologics Inc.'s free cash flow?
Abcellera Biologics Inc.'s free-cash-flow margin is -180.8% of revenue over the trailing twelve months, ranking 94 of the 176 biotechnology companies we cover.
Who are Abcellera Biologics Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Baker Bros. Advisors LP, Capital World Investors and Two Sigma Investments, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Abcellera Biologics Inc.'s market cap?
On November 2, 2026, Abcellera Biologics Inc.'s market capitalisation was about $3.4B and net debt of -$120M. Market figures come from third-party market data and may be delayed.
Who are Abcellera Biologics Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Abcellera Biologics Inc. are Cytokinetics Inc, Clinuvel Pharmaceuticals Ltd, Recursion Pharmaceuticals, Inc., Wave Life Sciences, Inc. and Viridian Therapeutics, Inc.\de. The side-by-side comparison below sets their revenue, margins and growth against Abcellera Biologics Inc.'s.
Are insiders buying or selling Abcellera Biologics Inc. stock?
Over the last 12 months, Abcellera Biologics Inc.'s directors and officers reported 9 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Abcellera Biologics Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Abcellera Biologics Inc. announces its own schedule.